Corona G, Giannini F, Fabris M, Toffoli G, Boiocchi M
Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Italy.
Int J Cancer. 1998 Jan 5;75(1):125-33. doi: 10.1002/(sici)1097-0215(19980105)75:1<125::aid-ijc19>3.0.co;2-f.
Folate receptor-alpha (FR-alpha) is generally over-expressed in non-mucinous human ovarian carcinomas. The meaning of FR-alpha over-expression and its role in the 5-methyltetrahydrofolic acid (N5-CH3-H4PteGlu) transport in such tumors is not clear, especially compared with the reduced folate carrier (RFC), the other known folate transporter. In this study, we analyzed molecular FR-alpha and RFC expression in 16 ovarian carcinoma tissues and in 5 ovarian carcinoma cell lines using competitive PCR. Co-expression of the 2 transporters was found both in vivo and in vitro. FR-alpha mRNA expression in the cell lines was in good agreement with the corresponding protein expression evaluated by cellular folic acid binding and immunofluorescence analysis, using a specific monoclonal antibody (MAb) (MOv18). Moreover, RFC mRNA expression levels were consistent with the selective cellular binding of N-hydroxysuccinimide of [3H]-methotrexate (NHS-MTX). The 5 ovarian carcinoma cell lines (IGROV-1, SW-626, SKOV-3, OVCAR-3 and OAW-42), grown at physiological N5-CH3-H4PteGlu concentrations (20 nM) and expressing FR-alpha and RFC levels superimposable to those observed in vivo, were used as in vitro cellular model to evaluate the different contribution of FR-alpha and RFC to the transport of N5-CH3-H4PteGlu. The cytoplasmic N5-CH3-[3H]H4PteGlu accumulation observed in each cell line was approximately linear over 4 hr of incubation, but there was no correlation between the rate of folate internalization and FR-alpha and RFC expression levels. Furthermore, the selective inhibition of FR-alpha and RFC functionality allowed us to distinguish their differential role on the overall N5-CH3-[3H]H4PteGlu intracellular delivery. Treatment with the N-hydroxysuccinimide of folic acid, which blocks FR-alpha activity, showed only a partial inhibition (about 20%) of folate internalization in all the cell lines. In contrast, the inhibition of RFC by NHS-MTX, under conditions that did not affect FR-alpha functionality, generally reduced folate accumulation by more than 70%. Only one cell line (IGROV-1) showed a comparable contribution of the 2 transport systems. Our findings suggest that in ovarian carcinomas, in spite of its over-expression, FR-alpha generally plays a minor role in N5-CH3-H4PteGlu transport compared with RFC.
叶酸受体-α(FR-α)在非黏液性人类卵巢癌中通常过度表达。FR-α过度表达的意义及其在这类肿瘤中5-甲基四氢叶酸(N5-CH3-H4PteGlu)转运中的作用尚不清楚,尤其是与另一种已知的叶酸转运体——还原型叶酸载体(RFC)相比。在本研究中,我们使用竞争性PCR分析了16例卵巢癌组织和5种卵巢癌细胞系中FR-α和RFC的分子表达。在体内和体外均发现了这两种转运体的共表达。细胞系中FR-α mRNA表达与通过细胞叶酸结合和免疫荧光分析(使用特异性单克隆抗体(MAb)(MOv18))评估的相应蛋白表达高度一致。此外,RFC mRNA表达水平与[3H]-甲氨蝶呤N-羟基琥珀酰亚胺酯(NHS-MTX)的细胞选择性结合一致。在生理N5-CH3-H4PteGlu浓度(20 nM)下生长且表达的FR-α和RFC水平与体内观察到的水平相当的5种卵巢癌细胞系(IGROV-1、SW-626、SKOV-3、OVCAR-3和OAW-42)被用作体外细胞模型,以评估FR-α和RFC对N5-CH3-H4PteGlu转运的不同贡献。在每个细胞系中观察到的细胞质N5-CH3-[3H]H4PteGlu积累在4小时孵育期间大致呈线性,但叶酸内化速率与FR-α和RFC表达水平之间没有相关性。此外,对FR-α和RFC功能的选择性抑制使我们能够区分它们在整体N5-CH3-[3H]H4PteGlu细胞内递送中的不同作用。用叶酸N-羟基琥珀酰亚胺酯处理可阻断FR-α活性,结果显示所有细胞系中叶酸内化仅受到部分抑制(约20%)。相反,在不影响FR-α功能的条件下,NHS-MTX对RFC的抑制通常使叶酸积累减少70%以上。只有一个细胞系(IGROV-1)显示出两种转运系统的贡献相当。我们的研究结果表明,在卵巢癌中,尽管FR-α过度表达,但与RFC相比,它在N5-CH3-H4PteGlu转运中通常起次要作用。